Over the last 7 days, the United States market has dropped 2.2%, yet it remains up by 18% over the past year with earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks involves looking for companies that not only demonstrate robust innovation and adaptability but also have strong potential to capitalize on these favorable long-term growth prospects.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 227 stocks from our US High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

BitFuFu

Simply Wall St Growth Rating: ★★★★★☆

Overview: BitFuFu Inc. operates in Singapore, offering digital asset mining and cloud-mining services, with a market capitalization of $871.53 million.

Operations: The company generates revenue primarily from its Internet Software & Services segment, amounting to $452.74 million.

BitFuFu, a dynamic player in the tech sector, has demonstrated remarkable financial performance with earnings growth of 1119.2% over the past year, significantly outpacing the software industry's average of 46.3%. This growth is supported by an aggressive expansion strategy, exemplified by their recent $20.4 million acquisition of a Bitcoin mining data center in Oklahoma, enhancing their operational capacity and efficiency in cryptocurrency mining. Furthermore, BitFuFu's innovative software service launch, BitFuFuOS, aims to optimize mining operations and profitability by up to 20%, indicating a strong focus on R&D and technological advancement to sustain its rapid revenue and earnings growth trajectory of 21.1% and 51% per year respectively.

• Unlock comprehensive insights into our analysis of BitFuFu stock in this health report.

• Gain insights into BitFuFu's historical performance by reviewing our past performance report.

MannKind

Simply Wall St Growth Rating: ★★★★☆☆

Overview: MannKind Corporation is a biopharmaceutical company specializing in the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States, with a market cap of approximately $1.59 billion.

Operations: MannKind focuses on inhaled therapeutic products, generating $267.20 million in revenue from its pharmaceuticals segment.

MannKind's trajectory in the high-growth tech landscape is underscored by its significant annual earnings growth forecast of 33.1%, outpacing the broader US market's projection of 14.3%. This growth is bolstered by strategic leadership changes, with new appointments poised to drive forward its biopharma and biotech sectors, reflecting a robust approach to innovation and market expansion. Recent clinical trial outcomes for Afrezza also highlight MannKind’s commitment to advancing medical technology, potentially enhancing its competitive edge in healthcare solutions.

• Click to explore a detailed breakdown of our findings in MannKind's health report.

• Review our historical performance report to gain insights into MannKind's's past performance.

Enfusion

Simply Wall St Growth Rating: ★★★★★☆

Overview: Enfusion, Inc. offers software-as-a-service solutions tailored for the investment management industry across various regions including the United States, Europe, the Middle East, Africa, and the Asia Pacific with a market capitalization of approximately $1.48 billion.

Operations: Enfusion generates revenue primarily through its online financial information provider segment, which accounts for $195.16 million. The company's focus on software-as-a-service solutions supports the investment management industry across multiple regions.

Enfusion, recently spotlighted for its robust annual earnings growth forecast at 74.8%, is demonstrating a significant competitive edge in the tech sector. Despite facing challenges with a -55.5% earnings dip over the past year, its strategic maneuvers, including a notable merger with Clearwater Analytics valued at approximately $1.1 billion, underscore its aggressive expansion strategy and potential market impact. This move not only reflects Enfusion's adaptability but also enhances shareholder value through strategic alliances, positioning it well amidst evolving market dynamics in technology and software industries.

• Take a closer look at Enfusion's potential here in our health report.

• Explore historical data to track Enfusion's performance over time in our Past section.

Turning Ideas Into Actions

• Explore the 227 names from our US High Growth Tech and AI Stocks screener here.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:FUFU NasdaqGM:MNKD and NYSE:ENFN.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com